Genetic Engineering & Biotechnology News

DEC 2017

Genetic Engineering & Biotechnology News (GEN) is the world's most widely read biotech publication. It provides the R&D community with critical information on the tools, technologies, and trends that drive the biotech industry.

Issue link:

Contents of this Issue


Page 52 of 69

The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada. DESIGN - ENGINEER - INNOVATE CRISPR For more information, visit © 2017 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. MilliporeSigma and the vibrant M are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources. Your complete line of CRISPR genome editing tools • The most comprehensive commercial screening portfolio from MilliporeSigma, the leader in lentiviral manufacturing • SygRNA™, synthetic crRNA and tracrRNA, in conjunction with Cas9 protein offer fast turnaround time to accelerate your experimental results • Exclusive partnership program for core facilities performing gene editing. Visit crisprcore for more information. 2017-08187 11/17

Articles in this issue

Links on this page

Archives of this issue

view archives of Genetic Engineering & Biotechnology News - DEC 2017